Belite Bio Inc reports results for the quarter ended March 31 - Earnings Summary
14/05/2025 22:01
Belite Bio Inc BLTE.OQ reported a quarterly adjusted loss of 45 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of four analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -44 cents to -30 cents per share. Reported revenue was zero; analysts expected zero. Belite Bio Inc's reported EPS for the quarter was a loss of 45 cents. The company reported a quarterly loss of $14.28 million. Belite Bio Inc shares had fallen by 8.0% this quarter and lost 3.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 4.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target for Belite Bio Inc is $90.00 This summary was machine generated from LSEG data May 14 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.37 | -0.45 | Missed |
| Dec. 31 2024 | -0.31 | -0.32 | Missed |
| Sep. 30 2024 | -0.29 | -0.28 | Beat |
| Jun. 30 2024 | -0.25 | -0.31 | Missed |
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses